Via: OncoMed
Expanded Phase of Trial will Assess anti-TIGIT in Combination with anti-PD1
REDWOOD CITY, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the first patient has been dosed in the company's Phase 1b portion of the Phase 1a/1b clinical trial of anti-TIGIT (OMP-313M32) in combination with anti-PD1 (nivolumab). TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is a next generation checkpoint receptor, and upon activation by the PVR ligand, a protein broadly expressed on tumor cells, it blocks T-cell activation. OncoMed's anti-TIGIT candidate is an IgG1 monoclonal antibody checkpoint inhibitor which binds to the human TIGIT receptor on T-cells with a goal of improving the activation and effectiveness of T-cell and NK cell tumor-killing activity.
"The dosing of the first patient in the Phase 1b portion of the anti-TIGIT trial marks an important milestone in the advancement of this therapeutic candidate through the clinic, where we will be evaluating the potential synergy of our anti-TIGIT monoclonal antibody with anti-PD1," said John Lewicki, Ph.D., president and chief executive officer of OncoMed. "We look forward to continuing our exploration of the potential anti-tumor activity of anti-TIGIT and its ability to combine safely with anti-PD1 in key clinical oncology settings. Simultaneously, dose escalation in the Phase 1a portion of the trial is nearing completion and dose expansion in select tumor types is planned."
Read More: http://www.oncomed.com/invest/releasedetail.cfm?ReleaseID=1069903
RSS Feed
